Clinical trial
Phase 2 Trial of Elranatamab With Cyclophosphamide in Relapsed/Refractory Multiple Myeloma
NCT07454382 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2 Trial of Elranatamab With Cyclophosphamide in Relapsed/Refractory Multiple Myeloma
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- February 27, 2026
- Completion date
- August 27, 2029
- Enrollment
- 26 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.